Results 291 to 300 of about 51,381 (340)
Some of the next articles are maybe not open access.
Chelation Therapy in Atherosclerosis
Annals of Internal Medicine, 1982Excerpt To the editor: A number of inquiries have been made to the West Virginia University Drug Information Center requesting information on the value of edetate disodium (EDTA) in chelation thera...
J G, Stevenson, T R, Covington
openaire +2 more sources
Combined iron chelation therapy
Annals of the New York Academy of Sciences, 2010Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications. Despite the availability of three iron chelators, some patients fail to respond adequately to monotherapy with any of them. Combination therapy, consisting in the use of two
Galanello Renzo +5 more
openaire +2 more sources
Chelation Therapy of Atherosclerosis
Drug Intelligence & Clinical Pharmacy, 1984Chelation therapy with intravenous injections of edetate disodium is being promoted to the public as a nonsurgical means to treat coronary or other arterial atherosclerosis. The rationale for use, clinical efficacy, and safety are reviewed. Acceptable evidence supporting chelation therapy for atherosclerotic vascular disease is lacking.
K L, Rathmann, L K, Golightly
openaire +2 more sources
Reviews in Clinical and Experimental Hematology, 2000
In chronic anemias associated with iron overload, iron chelation therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for the treatment of transfusional iron overload since the early 1960s, the era of modern and effective iron chelation ...
Chaim Hershko, A. Victor Hoffbrand
openaire +1 more source
In chronic anemias associated with iron overload, iron chelation therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for the treatment of transfusional iron overload since the early 1960s, the era of modern and effective iron chelation ...
Chaim Hershko, A. Victor Hoffbrand
openaire +1 more source
Chelation Therapy for Arteriosclerosis
JAMA: The Journal of the American Medical Association, 1975SOME profess that a certain intravenously administered colorless compound is the elixir of youth. Chelation therapy with edetate disodium (EDTA) solution is described in tones of evangelical fervor in a brochure from a medical clinic: Chelation therapy for hardening of the arteries is a special treatment given by licensed medical doctors for the ...
openaire +2 more sources
Seminars in Hematology, 2001
Iron chelators are used in clinical practice to protect patients from the complications of iron overload and iron toxicity because there is no physiologic way for excess iron to be actively excreted. Deferoxamine, the only iron-chelating agent available for clinical use in the United States, is administered as a prolonged (8 to 24 hours) infusion ...
openaire +2 more sources
Iron chelators are used in clinical practice to protect patients from the complications of iron overload and iron toxicity because there is no physiologic way for excess iron to be actively excreted. Deferoxamine, the only iron-chelating agent available for clinical use in the United States, is administered as a prolonged (8 to 24 hours) infusion ...
openaire +2 more sources
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Ca-A Cancer Journal for Clinicians, 2021Kyle Wang
exaly